{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:08:37Z","timestamp":1705018117556},"reference-count":14,"publisher":"Bentham Science Publishers Ltd.","issue":"26","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n<jats:title \/>\n<jats:p \/>\n<\/jats:sec>","DOI":"10.2174\/1381612829666230825103201","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T10:56:47Z","timestamp":1693306607000},"page":"2033-2035","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological Management of Resistant Hypertension in Moderate-to-advanced\nCKD: A Glance at Novel Non-steroidal MRAs"],"prefix":"10.2174","volume":"29","author":[{"given":"Panagiotis I.","family":"Georgianos","sequence":"first","affiliation":[{"name":"2nd Department of Nephrology, School of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, St. Kyriakidi 1, GR54636, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Vaios","sequence":"additional","affiliation":[{"name":"2nd Department of Nephrology, School of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, St. Kyriakidi 1, GR54636, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Karligkiotis","sequence":"additional","affiliation":[{"name":"2nd Department of Nephrology, School of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, St. Kyriakidi 1, GR54636, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Georgianou","sequence":"additional","affiliation":[{"name":"2nd Department of Nephrology, School of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, St. Kyriakidi 1, GR54636, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilios","family":"Liakopoulos","sequence":"additional","affiliation":[{"name":"2nd Department of Nephrology, School of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, St. Kyriakidi 1, GR54636, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"Noubiap J.J.","year":"2019","unstructured":"Noubiap J.J.; Nansseu J.R.; Nyaga U.F.; Sime P.S.; Francis I.; Bigna J.J.; Global prevalence of resistant hypertension: A meta-analysis of data from 3.2 million patients. Heart 2019,105(2),98-105","journal-title":"Heart"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11906-020-01081-x","volume":"22","author":"Georgianos P.I.","year":"2020","unstructured":"Georgianos P.I.; Agarwal R.; Resistant hypertension in chronic kidney disease (CKD): Prevalence, treatment particularities, and research agenda. Curr Hypertens Rep 2020,22(10),84","journal-title":"Curr Hypertens Rep"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.jacc.2012.12.061","volume":"61","author":"De Nicola L.","year":"2013","unstructured":"De Nicola L.; Gabbai F.B.; Agarwal R.; Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013,61(24),2461-2467","journal-title":"J Am Coll Cardiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams B.","year":"2018","unstructured":"Williams B.; Mancia G.; Spiering W.; 2018 ESC\/ESH Guidelines for the management of arterial hypertension. J Hypertens 2018,36(10),1953-2041","journal-title":"J Hypertens"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"Leon S.J.","year":"2022","unstructured":"Leon S.J.; Whitlock R.; Rigatto C.; Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: A population-based cohort study. Am J Kidney Dis 2022,80(2),164-173.e1","journal-title":"Am J Kidney Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"Trevisan M.","year":"2018","unstructured":"Trevisan M.; de Deco P.; Xu H.; Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail 2018,20(8),1217-1226","journal-title":"Eur J Heart Fail"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"Agarwal R.","year":"2019","unstructured":"Agarwal R.; Rossignol P.; Romero A.; Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019,394(10208),1540-1550","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","volume":"6","author":"Georgianos P.I.","year":"2021","unstructured":"Georgianos P.I.; Agarwal R.; Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int Rep 2021,6(9),2281-2291","journal-title":"Kidney Int Rep"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"Bakris G.L.","year":"2020","unstructured":"Bakris G.L.; Agarwal R.; Anker S.D.; Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020,383(23),2219-2229","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"Pitt B.","year":"2021","unstructured":"Pitt B.; Filippatos G.; Agarwal R.; Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021,385(24),2252-2263","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","volume":"16","author":"Agarwal R.","year":"2023","unstructured":"Agarwal R.; Pitt B.; Palmer B.F.; A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J 2023,16(2),293-302","journal-title":"Clin Kidney J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"Bakris G.L.","year":"2015","unstructured":"Bakris G.L.; Agarwal R.; Chan J.C.; Effect of finerenone on albuminuria in patients with diabetic nephropathy. JAMA 2015,314(9),884-894","journal-title":"JAMA"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","volume":"41","author":"Agarwal R.","year":"2023","unstructured":"Agarwal R.; Ruilope L.M.; Ruiz-Hurtado G.; Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens 2023,41(2),295-302","journal-title":"J Hypertens"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","volume":"78","author":"Bakris G.","year":"2021","unstructured":"Bakris G.; Pergola P.E.; Delgado B.; Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: Results of the BLOCK-CKD study. Hypertension 2021,78(1),74-81","journal-title":"Hypertension"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666230825103201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220342\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666230825103201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T13:36:33Z","timestamp":1704980193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220342\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":14,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612829666230825103201","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}